



# University of Pittsburgh

*School of Medicine*  
*Department Emergency Medicine*

Iroquois Building, Suite 400 A  
3600 Forbes Avenue  
Pittsburgh, PA 15261  
412-647-3078  
Fax: 412-647-6999

1 March 2021

Dear C3PO Research Participant,

I am writing with an important update about the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) and to thank you for your ongoing participation in this trial. On February 25, 2021, our Data Safety Monitoring Board looked at all of the information collected from the first 450 participants.

This Board concluded that enough people have now enrolled into the trial for us to answer the primary scientific question: whether getting convalescent plasma in the emergency department prevents mild COVID-19 from progressing to more serious illness. Therefore, they recommended, and we agreed to stop enrolling any more people into C3PO.

So far, convalescent plasma does not appear to increase or decrease the likelihood of COVID-19 patients getting worse. We still do not know whether plasma affects other outcomes such as symptoms or changes in the blood.

Because stopping enrollment in a large clinical trial is a very public action, you may see comments about C3PO in the news and in social media. The National Institutes of Health will make an official press release about the change in the trial status as well.

This note is to emphasize that your participation, your completion of the trial, and your data remain very important. What you tell us over the next few weeks about your symptoms and about how your body reacts to the infection will provide information to help understand how best to treat COVID-19. Therefore, please continue to complete the surveys, phone calls, or visits scheduled for you. If you have other questions, contact the investigators at the site where you enrolled in C3PO.

We hope that you are recovering well. Sharing your experience of your illness in a COVID-19 clinical trial provides knowledge that can guide treatment around the world for this and for future pandemics. It is a truly thoughtful and generous action on your part, and we are honored to work with you on this trial.

Best regards and rapid recovery,

A handwritten signature in blue ink that reads 'Clifton Callaway'.

Clifton W. Callaway, MD, PhD  
Co-Principal Investigator for C3PO Trial  
Professor and Vice-Chair of Emergency Medicine  
Ronald D. Stewart Endowed Chair of Emergency Medicine Research  
University of Pittsburgh